Seroatlas · Human Serome Atlas

TRMT5

tRNA (guanine(37)-N(1))-methyltransferase

Also known as: KIAA1393, TRM5, TRM5_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q32P41
Gene
TRMT5
Ensembl
ENSG00000126814
Chromosome
14
Canonical length
509 aa
Protein class
Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins
Subcellular location
Nucleoplasm,Nucleoli

OverviewNCBI Gene

tRNAs contain as many as 13 or 14 nucleotides that are modified posttranscriptionally by enzymes that are highly specific for particular nucleotides in the tRNA structure. TRMT5 methylates the N1 position of guanosine-37 (G37) in selected tRNAs using S-adenosyl methionine (Brule et al., 2004 [PubMed 15248782]).[supplied by OMIM, Mar 2008]

Canonical amino-acid sequenceUniProt

509 residues, UniProt reviewed canonical sequence.

>Q32P41|TRMT5
     1  MVLWILWRPF GFSGRFLKLE SHSITESKSL IPVAWTSLTQ MLLEAPGIFL LGQRKRFSTM
    61  PETETHERET ELFSPPSDVR GMTKLDRTAF KKTVNIPVLK VRKEIVSKLM RSLKRAALQR
   121  PGIRRVIEDP EDKESRLIML DPYKIFTHDS FEKAELSVLE QLNVSPQISK YNLELTYEHF
   181  KSEEILRAVL PEGQDVTSGF SRIGHIAHLN LRDHQLPFKH LIGQVMIDKN PGITSAVNKI
   241  NNIDNMYRNF QMEVLSGEQN MMTKVRENNY TYEFDFSKVY WNPRLSTEHS RITELLKPGD
   301  VLFDVFAGVG PFAIPVAKKN CTVFANDLNP ESHKWLLYNC KLNKVDQKVK VFNLDGKDFL
   361  QGPVKEELMQ LLGLSKERKP SVHVVMNLPA KAIEFLSAFK WLLDGQPCSS EFLPIVHCYS
   421  FSKDANPAED VRQRAGAVLG ISLEACSSVH LVRNVAPNKE MLCITFQIPA SVLYKNQTRN
   481  PENHEDPPLK RQRTAEAFSD EKTQIVSNT

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TRMT5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.35
Highest tissue expression
16 nTPM

Expression across tissuesHPA

Tissue

  • testis: 16 nTPM
  • parathyroid gland: 9.9 nTPM
  • breast: 9.1 nTPM
  • ovary: 8.5 nTPM
  • epididymis: 7.3 nTPM
  • esophagus: 7.2 nTPM

Single-cell type

  • early spermatids: 252 nCPM
  • late primary spermatocytes: 140 nCPM
  • late spermatids: 58 nCPM
  • erythrocyte progenitors: 29 nCPM
  • syncytiotrophoblasts: 26 nCPM
  • myosatellite cells: 23 nCPM

Immune cell

  • non-classical monocyte: 5.9 nTPM
  • intermediate monocyte: 5.5 nTPM
  • plasmacytoid DC: 5.2 nTPM
  • memory B-cell: 4.9 nTPM
  • T-reg: 4.5 nTPM
  • naive B-cell: 4.1 nTPM

Brain region

  • cerebellum: 16 nTPM
  • hypothalamus: 13 nTPM
  • cerebral cortex: 12 nTPM
  • white matter: 12 nTPM
  • basal ganglia: 11 nTPM
  • midbrain: 11 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about TRMT5.

Disease | AllUniProt

Conditions TRMT5 is implicated in, by any mechanism.

  • Peripheral neuropathy with variable spasticity, exercise intolerance, and developmental delay (PNSED) MIM:616539

Disease | GeneticClinVar

3 pathogenic / likely-pathogenic of 269 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Combined oxidative phosphorylation defect type 26

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.59
gnomAD pLI
0.05
gnomAD missense Z
0.1
DepMap mean gene effect
-0.78
DepMap dependency class
common

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TRMT5 as an antibody target. Whether an autoantibody or antibody against TRMT5 could matter depends on whether native TRMT5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TRMT5 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label TRMT5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/TRMT5. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...